Symbiotec Pharmalab IPO Day 1 Subscription Status: 0.48x Subscribed; GMP at ₹395
Symbiotec Pharmalab’s IPO was subscribed 0.48 times on Day 1, as of the afternoon (2:00 p.m. to 3:30 p.m. IST) on 24 August 2026. Employee demand led at 1.05x, followed by retail at 0.68x and Non-Institutional Investors (NIIs) at 0.63x, while Qualified Institutional Buyers (QIBs) had barely participated. The IPO remains open until 27 August. The latest available Grey Market Premium (GMP) was around ₹395.
| Metric | Latest update |
| Bidding day | Day 1 |
| Data status | Afternoon (2:00 p.m. to 3:30 p.m. IST) on 24 August 2026 |
| Overall subscription | 0.48x |
| QIB subscription | Below 0.01x |
| NII subscription | 0.63x |
| Retail subscription | 0.68x |
| Employee subscription | 1.05x |
| Current GMP | ₹395 |
| GMP percentage | About 40.0% |
| Indicative price | ₹1,383 |
| Closing date | 27 August 2026 |
Symbiotec Pharmalab IPO Day 1 Subscription Status
Category-wise bidding showed that demand was concentrated mainly among employees, retail bidders, and NIIs during the verified afternoon update.
| Investor category | Day 1 subscription |
| Qualified Institutional Buyers (QIBs) | Below 0.01x |
| Non-Institutional Investors (NIIs) | 0.63x |
| Retail Individual Investors | 0.68x |
| Employees | 1.05x |
| Overall | 0.48x |
The employee portion had crossed the shares reserved for that category, while the retail and NII portions were more than halfway subscribed. QIB participation remained negligible at this stage.
Subscription multiples measure the quantity of shares bid for relative to the shares available in each category. They do not represent the number of unique investors. A smaller reserved category can also reach a higher multiple with fewer shares bid than a larger category.
What the Day 1 Subscription Numbers Indicate So Far
The opening response was not yet broad-based. Employee demand had crossed 1x, while retail and NII bidding accounted for most of the public demand seen so far.
Institutional participation is still an incomplete signal because QIB bids often build later in an IPO’s bidding period. That historical pattern should not be treated as a prediction that institutional demand will necessarily rise in this issue.
At 0.48x overall, the Day 1 figure therefore provides an early snapshot rather than a verdict on final demand.
Symbiotec Pharmalab IPO GMP Today and Estimated Listing Price
The latest available Symbiotec Pharmalab IPO GMP was around ₹395 per share as of the afternoon (2:00 p.m. to 3:30 p.m. IST) on 24 August 2026.
At the upper price band of ₹988:
Indicative price = ₹988 + ₹395 = ₹1,383
GMP percentage = ₹395 ÷ ₹988 × 100 = about 40.0%
One other tracker showed a reading near ₹403 earlier in the afternoon, while available grey-market trackers showed readings broadly ranging from about ₹380 to ₹409. The variation matters because GMP is an unofficial and unregulated market indicator, not an exchange-published price.
Compared with the earlier ₹403 reading, the ₹395 observation represents a small ₹8 decline. GMP can change quickly and does not guarantee either the actual listing price or listing gains.
What Stands Out in Today’s Bidding
Two signals are worth monitoring. First, employee demand crossed 1x while the wider issue remained below full subscription, showing that demand was uneven across categories. Second, retail and NII participation had developed faster than QIB participation during the verified afternoon period.
There are also important limitations. Day 1 data is incomplete, especially for categories where bids may arrive later. Further, the roughly 40% GMP is much stronger than the 0.48x overall subscription level, but the two indicators are not directly comparable. Subscription measures formal bids, while GMP reflects unofficial grey-market sentiment.
Neither high GMP nor a later rise in subscription would establish fair valuation, business quality, or future returns.
IPO Details Retail Investors Need
| IPO detail | Information |
| Price band | ₹938 to ₹988 per share |
| Lot size | 15 shares |
| Minimum retail investment | ₹14,820 at upper band |
| Issue size | About ₹1,757 crore |
| Fresh issue | ₹150 crore |
| Offer for Sale (OFS) | About ₹1,607 crore |
| Issue type | Book-built mainboard IPO |
| Closing date | 27 August 2026 |
| Expected listing date | 1 September 2026 |
| Exchange | BSE and NSE |
The Offer for Sale (OFS) forms the majority of the issue, meaning most of the IPO proceeds will go to selling shareholders rather than the company.
Brief Company and Financial Context
Symbiotec Pharmalab manufactures Active Pharmaceutical Ingredients (APIs), nutritional ingredients, and specialised pharmaceutical products, with international markets contributing a substantial share of revenue. Total revenue rose from about ₹755.98 crore in FY2025 to ₹872.26 crore in FY2026, while Profit After Tax (PAT) increased from ₹96.79 crore to ₹109.90 crore.
Of the ₹150 crore fresh issue, about ₹112.5 crore is intended for repayment or prepayment of borrowings, with the balance available for general corporate purposes. One material consideration is product concentration, with the company’s top five products contributing a sizeable share of revenue.
What Happens Next
Day 2 bidding on 25 August will show whether the opening demand broadens beyond employees, retail investors, and NIIs. Investors tracking the issue can watch the overall subscription pace, QIB participation, changes in NII and retail demand, and whether GMP remains near its current range or moves materially.
The IPO is scheduled to remain open through 27 August 2026.
Frequently Asked Questions (FAQs)
Q: How many times was the Symbiotec Pharmalab IPO subscribed on Day 1?
A: Symbiotec Pharmalab IPO was subscribed 0.48x overall as of the afternoon (2:00 p.m. to 3:30 p.m. IST) on 24 August 2026. Employee demand stood at 1.05x, retail at 0.68x, and NII at 0.63x.
Q: What is the Symbiotec Pharmalab IPO GMP today?
A: The latest available Grey Market Premium was around ₹395 per share as of the afternoon (2:00 p.m. to 3:30 p.m. IST) on 24 August 2026. Different trackers showed readings of roughly ₹380 to ₹409, reflecting the unofficial nature of GMP.
Q: What listing price does the current Symbiotec Pharmalab IPO GMP indicate?
A: A ₹395 GMP added to the ₹988 upper price band gives an indicative price of about ₹1,383 per share. This is only a grey-market calculation and does not predict or guarantee the actual listing price.
Q: Is the Symbiotec Pharmalab IPO Day 1 subscription figure final?
A: No. The 0.48x figure is an interim Day 1 reading from the afternoon of 24 August 2026. Bids can continue to change through the remaining bidding period, which ends on 27 August 2026.
Q: Does high IPO subscription or GMP guarantee a premium listing?
A: No. Subscription data measures formal bidding demand, while GMP is an unofficial sentiment indicator. Neither guarantees a premium listing, fair valuation, strong business performance, or future investment returns.
Disclaimer
The stocks mentioned in this article are not recommendations. Please conduct your own research and due diligence before investing. Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please read the Risk Disclosure documents carefully before investing in Equity Shares, Derivatives, Mutual fund, and/or other instruments traded on the Stock Exchanges. As investments are subject to market risks and price fluctuation risk, there is no assurance or guarantee that the investment objectives shall be achieved. Lemonn (Formerly known as NU Investors Technologies Pvt. Ltd) do not guarantee any assured returns on any investments. Past performance of securities/instruments is not indicative of their future performance.
